The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Oral Treatment With α-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy
Open accessAbstract
OBJECTIVE—The aim of this trial was to evaluate the effects of α-lipoic acid (ALA) on positive sensory symptoms and neuropathic deficits in diabetic patients with distal symmetric polyneuropathy (DSP). RESEARCH DESIGN AND METHODS—In this multicenter, randomized, double-blind, placebo-controlled trial, 181 diabetic patients in Russia and Israel received once-daily oral doses of 600 mg (n = 45) (ALA600), 1,200 mg (n = 47) (ALA1200), and 1,800 mg (ALA1800) of ALA (n = 46) or placebo (n = 43) for 5 weeks after a 1-week placebo run-in period. The primary outcome measure was the change from baseline of the Total Symptom Score (TSS), including stabbing pain, burning pain, paresthesia, and asleep numbness of the feet. Secondary end points included individual symptoms of TSS, Neuropathy Symptoms and Change (NSC) score, Neuropathy Impairment Score (NIS), and patients’ global assessment of efficacy. RESULTS—Mean TSS did not differ significantly at baseline among the treatment groups and on average decreased by 4.9 points (51%) in ALA600, 4.5 (48%) in ALA1200, and 4.7 (52%) in ALA1800 compared with 2.9 points (32%) in the placebo group (all P < 0.05 vs. placebo). The corresponding response rates (≥50% reduction in TSS) were 62, 50, 56, and 26%, respectively. Significant improvements favoring all three ALA groups were also noted for stabbing and burning pain, the NSC score, and the patients’ global assessment of efficacy. The NIS was numerically reduced. Safety analysis showed a dose-dependent increase in nausea, vomiting, and vertigo. CONCLUSIONS—Oral treatment with ALA for 5 weeks improved neuropathic symptoms and deficits in patients with DSP. An oral dose of 600 mg once daily appears to provide the optimum risk-to-benefit ratio.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boulton, A. J. M., Vinik, A. I., Arezzo, J. C., Bril, V., Feldman, E. L., Freeman, R., Malik, R. A., Maser, R. E., Sosenko, J. M., & Ziegler, D. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.956 · Cited by 1,859
Self-citationAlgorithm for neuropathic pain treatment: An evidence based proposal
Finnerup, N. B., Otto, M., McQuay, H. J., Jensen, T. S., & Sindrup, S. H. (2005) · Pain · doi:10.1016/j.pain.2005.08.013 · Cited by 1,330
Oxidative Stress in the Pathogenesis of Diabetic Neuropathy
Vincent, A. M., Russell, J. W., Low, P., & Feldman, E. L. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0019 · Cited by 982
Self-citationBoulton, A. J. M., Malik, R. A., Arezzo, J. C., & Sosenko, J. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1458 · Cited by 913
Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy
Cameron, N. E., Eaton, S. E. M., Cotter, M. A., & Tesfaye, S. (2001) · Diabetologia · doi:10.1007/s001250100001 · Cited by 701
Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life
Galer, B. S., Gianas, A., & Jensen, M. P. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00112-6 · Cited by 601
Detection, characterization, and staging of polyneuropathy: Assessed in diabetics
Dyck, P. J. (1988) · Muscle & Nerve · doi:10.1002/mus.880110106 · Cited by 555
Self-citationTreatment of symptomatic diabetic polyneuropathy with the antioxidant α‐lipoic acid: a meta‐analysis
Ziegler, D., Nowak, H., Kempler, P., Vargha, P., & Low, P. A. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01109.x · Cited by 551
Self-citationZiegler, D., Hanefeld, M., Ruhnau, K. J., Mei\ner, H. P., Lobisch, M., Sch�tte, K., Gries, F. A., & The ALADIN Study Group (1995) · Diabetologia · doi:10.1007/bf00400603 · Cited by 525
Self-citationDaousi, C., MacFarlane, I. A., Woodward, A., Nurmikko, T. J., Bundred, P. E., & Benbow, S. J. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01271.x · Cited by 454
Cited by
Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0092-1 · Cited by 1,697
Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential
Shay, K. P., Moreau, R. F., Smith, E. J., Smith, A. R., & Hagen, T. M. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.07.026 · Cited by 976
Sivitz, W. I., & Yorek, M. A. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2531 · Cited by 742
Repurposing Diflunisal for Familial Amyloid Polyneuropathy: A Randomized Clinical Trial
Berk, J. L., Suhr, O. B., Obici, L., Sekijima, Y., Zeldenrust, S. R., Yamashita, T., Heneghan, M. A., Gorevic, P. D., Litchy, W. J., Wiesman, J. F., et al. (2013) · JAMA · doi:10.1001/jama.2013.283815 · Cited by 708
Self-citationHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Said, G. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0504 · Cited by 615
Diabetic neuropathy: cellular mechanisms as therapeutic targets
Vincent, A. M., Callaghan, B. C., Smith, A. L., & Feldman, E. L. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.137 · Cited by 566
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Sloan, G., Selvarajah, D., & Tesfaye, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00496-z · Cited by 534
Diabetic Microvascular Disease: An Endocrine Society Scientific Statement
Barrett, E. J., Liu, Z., Khamaisi, M., King, G. L., Klein, R., Klein, B. E. K., Hughes, T. M., Craft, S., Freedman, B. I., Bowden, D. W., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01922 · Cited by 515
Ziegler, D., Low, P. A., Litchy, W. J., Boulton, A. J. M., Vinik, A. I., Freeman, R., Samigullin, R., Tritschler, H., Munzel, U., Maus, J., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0503 · Cited by 401
Self-citationDworkin, R. H., Turk, D. C., Peirce-Sandner, S., Baron, R., Bellamy, N., Burke, L. B., Chappell, A., Chartier, K., Cleeland, C. S., Costello, A., et al. (2010) · Pain · doi:10.1016/j.pain.2010.02.018 · Cited by 381
Painful Diabetic Neuropathy: Epidemiology, Natural History, Early Diagnosis, and Treatment Options
Veves, A., Backonja, M., & Malik, R. A. (2008) · Pain Medicine · doi:10.1111/j.1526-4637.2007.00347.x · Cited by 375
Diabetic Neuropathy: Mechanisms, Emerging Treatments, and Subtypes
Albers, J. W., & Pop-Busui, R. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0473-5 · Cited by 357
Challenges of neuropathic pain: focus on diabetic neuropathy
Rosenberger, D. C., Blechschmidt, V., Timmerman, H., Wolff, A., & Treede, R.-D. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02145-7 · Cited by 325
Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets
Dewanjee, S., Das, S., Das, A. K., Bhattacharjee, N., Dihingia, A., Dua, T. K., Kalita, J., & Manna, P. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.034 · Cited by 300
Diabetic Painful and Insensate Neuropathy: Pathogenesis and Potential Treatments
Obrosova, I. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.07.004 · Cited by 272
Diabetes and Alpha Lipoic Acid
Golbidi, S., Badran, M., & Laher, I. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00069 · Cited by 270
Gomes, M. B., & Negrato, C. A. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-80 · Cited by 269
Diabetic Bladder Dysfunction: Current Translational Knowledge
Daneshgari, F., Liu, G., Birder, L., Hanna-Mitchell, A. T., & Chacko, S. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.08.070 · Cited by 265
Dyslipidemia-Induced Neuropathy in Mice
Vincent, A. M., Hayes, J. M., McLean, L. L., Vivekanandan-Giri, A., Pennathur, S., & Feldman, E. L. (2009) · Diabetes · doi:10.2337/db09-0047 · Cited by 264
Understanding Diabetic Neuropathy: Focus on Oxidative Stress
Pang, L., Lian, X., Liu, H., Zhang, Y., Li, Q., Cai, Y., Ma, H., & Yu, X. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9524635 · Cited by 184
Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction
Szabo, C. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00086.x · Cited by 165
“…Journal of Pharmacology (2009) 156 713–727 rupt target organ damage when given chronically to diabetic animals (Kowluru and Odenbach, 2004; Lin et al., 2006) and has also produced encouraging clinical effects in human diabetes trials (Ziegler et al., 2006; Foster, 2007; Du et al., 2008).”
BackgroundTreating pain in diabetic neuropathy: current and developmental drugs
Alam, U., Sloan, G., & Tesfaye, S. (2020) · Drugs · doi:10.1007/s40265-020-01259-2 · Cited by 104
Bobe, G., Michels, A. J., Zhang, W.-J., Purnell, J. Q., Woffendin, C., Pereira, C., Vita, J. A., Thomas, N. O., Traber, M. G., Frei, B., et al. (2020) · The Journal of Nutrition · doi:10.1093/jn/nxaa203 · Cited by 22
Metadata
- Authors
- Ziegler, D., Ametov, A., Barinov, A., Dyck, P. J., Gurieva, I., Low, P. A., Munzel, U., Yakhno, N., Raz, I., Novosadova, M., Maus, J., & Samigullin, R.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-11-01
- Volume
- 29
- Issue
- 11
- Pages
- 2365-2370
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2037682503
- Cited by
- 562
- References
- 33
- FWCI
- 12.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.